Dean Berry to Join MarketAxess as Group COO and CEO of EMEA & APAC
In this new role, Mr. Berry will have oversight of MarketAxess Global Operations, Risk, Product and Technology, in addition to his role as CEO of the EMEA and APAC businesses.
'Not only does Dean have a consistent track record of scaling businesses profitably through technology and product transformation, but he also brings with him a deep expertise in managing trading workflows and analytics, alongside significant electronic trading and markets experience,' said Chris Concannon, Chief Executive Officer at MarketAxess. "I look forward to the addition of Dean to my global management team and his help in driving our strategy to accelerate innovation and efficiency across fixed-income markets globally."
Mr. Berry will join MarketAxess from LSEG where he was Group Head of its Workflows businesses since January 2024 and interim co-Head of LSEG's Data & Analytics business since December 2024. Prior to these roles, he served as LSEG's Global Head of Trading & Banking Solutions and Global Head of Trading. Prior to LSEG, he was the Global Head of Electronic & Hybrid Markets at BGC Partners. Mr. Berry spent the first 16 years of his career as a fixed-income trader at Deutsche Bank, Dresdner Kleinwort Wasserstein and Société Générale. He brings extensive overseas experience gained through previous roles in Singapore, Tokyo, Copenhagen, Frankfurt and London.
"I am excited to be joining the team at MarketAxess," said Mr. Berry. 'I believe my previous experience as both a fixed-income trader and as a champion of electronic trading, as well as my track record of profitable product-led innovation, will set us up for continued success.'
Mr. Berry is expected to join MarketAxess in Q4 2025. He will be based in the London office and will report to Chris Concannon.
About MarketAxess
MarketAxess (Nasdaq: MKTX) operates a leading electronic trading platform that delivers greater trading efficiency, a diversified pool of liquidity and significant cost savings to institutional investors and broker-dealers across the global fixed-income markets. Approximately 2,100 firms leverage MarketAxess' patented technology to efficiently trade fixed-income securities. Our automated and algorithmic trading solutions, combined with our integrated and actionable data offerings, help our clients make faster, better-informed decisions on when and how to trade on our platform. MarketAxess' award-winning Open Trading ® marketplace is widely regarded as the preferred all-to-all trading solution in the global credit markets. Founded in 2000, MarketAxess connects a robust network of market participants through an advanced full trading lifecycle solution that includes automated trading solutions, intelligent data and index products and a range of post-trade services. Learn more at www.marketaxess.com and on X @MarketAxess.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements, including statements within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995 with respect to the Company's strategy and business outcomes. These and other statements that relate to future results and events are based on MarketAxess' current expectations. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release. Please refer to the periodic filings MarketAxess makes with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause events and results to differ materially from those contained in the forward-looking statements set forth in this press release. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. More information about these and other factors affecting MarketAxess' business and prospects is contained in MarketAxess' periodic filings with the Securities and Exchange Commission and can be accessed at www.marketaxess.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
What To Expect From Lindblad Expeditions's (LIND) Q2 Earnings
Cruise and exploration company Lindblad Expeditions (NASDAQ:LIND) will be reporting results this Monday before market open. Here's what you need to know. Lindblad Expeditions beat analysts' revenue expectations by 18.8% last quarter, reporting revenues of $179.7 million, up 17% year on year. It was an exceptional quarter for the company, with an impressive beat of analysts' EPS estimates and a solid beat of analysts' EBITDA estimates. Is Lindblad Expeditions a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Lindblad Expeditions's revenue to grow 16.5% year on year to $159 million, improving from the 9.4% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.29 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Lindblad Expeditions has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 5.8% on average. Looking at Lindblad Expeditions's peers in the travel and vacation providers segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Carnival delivered year-on-year revenue growth of 9.5%, beating analysts' expectations by 1.7%, and Delta reported flat revenue, topping estimates by 1.5%. Carnival traded up 5.9% following the results while Delta was also up 11.9%. Read our full analysis of Carnival's results here and Delta's results here. Investors in the travel and vacation providers segment have had steady hands going into earnings, with share prices flat over the last month. Lindblad Expeditions is down 7.4% during the same time and is heading into earnings with an average analyst price target of $15 (compared to the current share price of $11.73). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
35 minutes ago
- Yahoo
PlayStudios (MYPS) To Report Earnings Tomorrow: Here Is What To Expect
Digital casino game platform PlayStudios (NASDAQ:MYPS) will be announcing earnings results this Monday after market hours. Here's what you need to know. PlayStudios missed analysts' revenue expectations by 1.4% last quarter, reporting revenues of $62.71 million, down 19.4% year on year. It was a satisfactory quarter for the company, with a solid beat of analysts' adjusted operating income estimates but a miss of analysts' daily active users estimates. It reported 2.63 million monthly active users, down 24.7% year on year. Is PlayStudios a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting PlayStudios's revenue to decline 15.9% year on year to $61.07 million, a further deceleration from the 6.7% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.03 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. PlayStudios has missed Wall Street's revenue estimates five times over the last two years. Looking at PlayStudios's peers in the consumer discretionary segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Rush Street Interactive delivered year-on-year revenue growth of 22.2%, beating analysts' expectations by 7.6%, and Churchill Downs reported revenues up 4.9%, topping estimates by 1.4%. Rush Street Interactive traded up 25.7% following the results while Churchill Downs was also up 4.1%. Read our full analysis of Rush Street Interactive's results here and Churchill Downs's results here. Investors in the consumer discretionary segment have had steady hands going into earnings, with share prices flat over the last month. PlayStudios is down 10.7% during the same time and is heading into earnings with an average analyst price target of $2.88 (compared to the current share price of $1.09). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
35 minutes ago
- Yahoo
What To Expect From Vertex Pharmaceuticals's (VRTX) Q2 Earnings
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting earnings this Monday after the bell. Here's what to look for. Vertex Pharmaceuticals missed analysts' revenue expectations by 2.3% last quarter, reporting revenues of $2.77 billion, up 3% year on year. It was a disappointing quarter for the company, with a significant miss of analysts' EPS estimates and full-year revenue guidance slightly missing analysts' expectations. Is Vertex Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Vertex Pharmaceuticals's revenue to grow 9.8% year on year to $2.90 billion, improving from the 6.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $4.25 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Vertex Pharmaceuticals has missed Wall Street's revenue estimates three times over the last two years. Looking at Vertex Pharmaceuticals's peers in the therapeutics segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Biogen delivered year-on-year revenue growth of 7.3%, beating analysts' expectations by 13.7%, and Moderna reported a revenue decline of 41.1%, topping estimates by 10.7%. Biogen traded up 3.9% following the results. Read our full analysis of Biogen's results here and Moderna's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the therapeutics stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Vertex Pharmaceuticals's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $505.19 (compared to the current share price of $464). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
